(Press-News.org) The first clinical trials on a new investigational drug being developed to treat infections caused by Hepatitis C virus have been successfully completed.
Completion of the initial phase (phase 1a) of trials of INX-189, discovered and first prepared by researchers at Cardiff University's Welsh School of Pharmacy in 2008, means the chances of it becoming an approved medicine have significantly improved.
Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation in western countries. The current treatment involves two drugs – ribavirin and interferon, which has to be given as an injection. Side effects are often severe and lead to patients failing to complete the treatment.
Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project, said: "This is still a very early stage of the trials process but none the less a significant development. Successfully completing phase 1a demonstrates that the drug is safe, with no drug-related side effects at all in a single dose of 100mg.
"The efficiency of drug release in this study has also confirmed that one single dose a day is most likely enough in treating the virus.
"We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."
In 2008, laboratory tests showed INX-189 killed 90 per cent of the virus at very low (nanomolar) concentration, making it the most potent compound of its kind developed to date.
US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, has announced it is looking forward to a second trial (phase 1b), which would evaluate the compound's effectiveness in Hepatitis C patients.
Cardiff University and Inhibitex filed a patent on INX-189 earlier this year. It has been cleared for human clinical trials by the Food and Drug Administration in the US.
INFORMATION:
Notes for Editors
For further information please contact:
Professor Chris McGuigan,
Welsh School of Pharmacy,
Cardiff University,
Telephone +44 029 2087 4537
Email: mcguigan@cardiff.ac.uk
Lowri Jones
Public Relations,
Cardiff University.
029 20 870995
e-mail: RouseS@cardiff.ac.uk
INX-189
Inhibitex has initiated a Phase I double-blind, placebo-controlled, single ascending dose study to evaluate the safety and pharmacokinetic activity of INX-189 in healthy volunteers under an IND that it filed earlier this year with the FDA. The study, which is being conducted in the U.S., will evaluate up to six escalating doses of INX-189, ranging from 3 mg up to200 mg. Each dose cohort will include eight subjects, six of which will receive INX-189 and two that will receive placebo.
Inhibitex is developing a series of proprietary protides of nucleoside inhibitors that target the RNA-dependent RNA polymerase (NS5b) of HCV. The Company believes that its protides possess several pharmacological advantages over nucleosides alone, including greater potency, a more rapid conversion into its active form in the liver and potentially less toxicity due to reduced systemic exposure of the nucleoside. INX-189 is a protide of a 2'-C-methylguanosine analogue, which the Company believes is the most potent HCV nucleotide polymerase inhibitor described in the literature to date. The Company believes that preclinical studies of INX-189 support its potential as a highly potent, once-per-day oral therapy highly amenable to combination with other antivirals for the treatment of patients with chronic hepatitis C infection.
About Inhibitex
Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company's pipeline includes FV-100, which is in Phase II clinical development for the treatment of shingles, and INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections. Both programmes were in licensed from and pursued collaboratively with Cardiff University. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of staphylococcal vaccines. For additional information about the Company, please visit www.inhibitex.com.
Cardiff University
Cardiff University is recognised in independent government assessments as one of Britain's leading teaching and research universities and is a member of the Russell Group of the UK's most research intensive universities. Among its academic staff are two Nobel Laureates, including the winner of the 2007 Nobel Prize for Medicine, Professor Sir Martin Evans.
Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The University's breadth of expertise in research and research-led teaching encompasses: the humanities; the natural, physical, health, life and social sciences; engineering and technology; preparation for a wide range of professions; and a longstanding commitment to lifelong learning.
ESA's Envisat satellite has been tracking the progression of the giant iceberg that calved from Greenland's Petermann glacier on 4 August 2010. This animation shows that the iceberg, the largest in the northern hemisphere, is now entering Nares Strait – a stretch of water that connects the Lincoln Sea and Arctic Ocean with Baffin Bay.
The Petermann glacier in northern Greenland is one of the largest of the country's glaciers – and until August it had a 70 km tongue of floating ice extending out into the sea. The glacier regularly advances towards the sea at about 1 km ...
CAMDEN — One mention of E. coli conjures images of sickness and food poisoning, but the malevolent bacteria may also be the key to the future of renewable energy.
Desmond Lun, an associate professor of computer science at Rutgers University–Camden, is researching how to alter the genetic makeup of E. coli to produce biodiesel fuel derived from fatty acids.
"If we can engineer biological organisms to produce biodiesel fuels, we'll have a new way of storing and using energy," Lun says.
Creating renewable energy by making fuels, like making ethanol out of corn, has been ...
Only about one in every six Americans who have ever been overweight or obese loses weight and maintains that loss, according to Penn State College of Medicine researchers.
While that number is larger than most weight-loss clinical trials report, the majority of Americans are still unable to lose weight and keep it off. Identifying those who lose weight and successfully maintain that loss may aid health professionals in developing approaches to help others maintain weight loss, the researchers say.
Two-thirds of the United States adult population is overweight, defined ...
Ten years on, Martin McKee reflects on report placed health system performance rankings firmly on political agenda.
Martin McKee, Professor of European Health at the London School of Hygiene & Tropical Medicine has contributed one of three commentaries appearing today in the journal Health Policy and Planning, each of which take a different perspective on the World Health Report 2000 on health systems (WHR2000).
It is ten years since the publication of WHR2000, a controversial document which many at the time believed had been published prematurely, and which introduced ...
Hurricane Earl lashed the North Carolina coast last night and this morning, September 3, and is now headed for Cape Cod, Massachusetts. This morning's image from the GOES-13 satellite saw Hurricane Earl's clouds covering most of the northeastern U.S.
The Geostationary Operational Environmental Satellite known as GOES-13 captured an image of Hurricane Earl at 7:32 a.m. EDT this morning, September 3. The image clearly showed a huge Hurricane Earl northeast of North Carolina with cloud cover stretching over the northeastern U.S. A disorganized Fiona was also seen southeast ...
Hurricane Earl, currently a Category Two storm on the Saffir-Simpson scale with maximum sustained winds of 100 knots (115 miles per hour), continues to push relentlessly toward the U.S. East Coast, and NASA scientists, instruments and spacecraft are busy studying the storm from the air and space. Three NASA aircraft carrying 15 instruments are busy criss-crossing Earl as part of the agency's Genesis and Rapid Intensification Processes mission, or GRIP, which continues through Sept. 30. GRIP is designed to help improve our understanding of how hurricanes such as Earl form ...
VERNON -- Dr. Dariusz Malinowski is seeing blue, and he is very excited.
For four years, Malinowski, an AgriLife Research plant physiologist and forage agronomist in Vernon, has been working with collaborators Steve Brown of the Texas Foundation Seed and Dr. William Pinchak and Shane Martin with AgriLife Research on a winter-hardy hibiscus breeding project.
The project was first a private hobby of the inventors and became a part of the strategic plan of the Texas AgriLife Research and Extension Center at Vernon in 2009. The flower commercialization is a part ...
Researchers at Queen's University have found that people with Parkinson's disease can perform automated tasks better than people without the disease, but have significant difficulty switching from easy to hard tasks. The findings are a step towards understanding the aspects of the illness that affect the brain's ability to function on a cognitive level.
"We often think of Parkinson's disease as being a disorder of motor function," says Douglas Munoz, director of the Queen's Centre for Neuroscience Studies and a Canada Research Chair in Neuroscience. "But the issue is ...
While vultures across Asia teeter on the brink of extinction, the vultures of Cambodia are increasing in number, providing a beacon of hope for these threatened scavengers, according to the Wildlife Conservation Society (WCS) and other members of the Cambodia Vulture Conservation Project.
Researchers report that record numbers of vultures have been counted in Cambodia's annual vulture census, with 296 birds of three species found at multiple sites across the Northern and Eastern Plains of Cambodia by the Cambodia Vulture Conservation Project, a partnership of conservationists ...
Afla-Guard®, a biological control used to thwart the growth of fungi on peanuts, can be used on corn as well, according to a study by U.S. Department of Agriculture (USDA) scientists who helped develop it.
After extensive study and research trials in Texas, Afla-Guard® was registered by the U.S. Environmental Protection Agency (EPA) for use on corn, beginning with the 2009 crop.
Recently retired Agricultural Research Service (ARS) microbiologist Joe Dorner at the National Peanut Research Laboratory in Dawson, Ga., helped develop Afla-Guard®, a biological control for ...
